Company Overview
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. The company was founded in 2014 and is based in Guilford, Connecticut.
Why Investors Should Care
Net profit has compounded at 17.1% per year over the last five years.
Revenue has grown at a 25.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.36.
Recent Developments
- Dec 2025 Revenue of $13.56M (+5.2% YoY); net profit $-35.57M.
- Trailing 12 Months Year-on-year growth — revenue +44.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 25.8%, profit CAGR 17.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 25.79% |
| 1 Year: | 44.80% |
Compounded Profit Growth
| 5 Years: | 17.13% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -35.29% |
| 6 Months: | -29.16% |
| 3 Months: | -41.72% |
| 1 Month: | -13.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)34.49 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 25.8% over 5 years.
- Profit CAGR of 17.1% over 5 years.
CONS
- Trading 62.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HYPR Hyperfine, Inc. PHARMA | 0.82 | -2.22 | $74.61M | 0.00% | -85.19% | -96.97% | 25.79% | 17.13% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 331.00K | 358.00K | 371.00K | 1.51M | 1.53M | 2.35M | 2.63M | 3.38M | 2.33M | 3.29M | 3.63M | 3.64M | 2.14M | 2.70M | 3.44M | 5.29M | 3.90M | 3.90M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 1.25M | 1.37M | 1.59M | 2.60M | 1.92M | - |
| Gross Profit | -277.00K | -99.00K | -338.00K | 84.00K | -165.00K | 688.00K | 1.16M | 1.44M | 1.12M | 1.35M | 1.80M | 1.91M | 883.00K | 1.33M | 1.85M | 2.69M | 1.98M | 1.98M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 11.79M | 10.92M | 10.77M | 10.36M | 10.54M | - |
| Operating Income | -7.80M | -14.59M | -16.39M | -23.77M | -23.19M | -13.28M | -13.04M | -11.69M | -11.76M | -10.65M | -10.85M | -10.96M | -10.90M | -9.60M | -8.92M | -7.67M | -8.56M | -8.47M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -9.19M | -9.31M | -8.62M | -7.39M | -8.27M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 83.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -9.42M | -9.22M | -11.02M | -5.91M | -8.62M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | -7.79M | -14.58M | -16.39M | -23.77M | -23.16M | -13.17M | -12.16M | -10.64M | -10.76M | -9.85M | -10.16M | -10.33M | -9.42M | -9.22M | -11.02M | -5.91M | -8.62M | -9.30M |
| Diluted EPS | - | -8.80 | -8.66 | -0.34 | -0.33 | -0.19 | -0.17 | -0.15 | -0.15 | -0.14 | -0.14 | -0.14 | -0.12 | -0.12 | -0.14 | -0.06 | -0.09 | -0.09 |
| R&D Expense | 4.47M | 6.04M | 6.44M | 8.33M | 7.26M | 7.34M | 5.46M | 5.33M | 5.74M | 5.57M | 5.96M | 5.87M | 5.04M | 4.54M | 4.05M | - | 3.85M | 3.87M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 294.00K | 1.50M | 6.81M | 11.03M | 12.89M | 13.56M |
| Cost of Revenue | - | - | 5.91M | 6.28M | 7.00M | 6.81M |
| Gross Profit | -477.00K | -1.17M | 907.00K | 4.76M | 5.89M | 6.75M |
| Operating Expenses | - | - | 74.78M | 52.87M | 49.12M | 43.84M |
| Operating Income | -23.49M | -64.87M | -73.87M | -48.12M | -43.22M | -37.09M |
| EBITDA | - | - | -72.86M | -47.06M | -42.22M | -35.99M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -73.16M | -44.24M | -40.72M | -35.57M |
| Tax Provision | - | - | 0 | 0 | 0 | 0 |
| Net Income | -23.43M | -64.85M | -73.16M | -44.24M | -40.72M | -35.57M |
| Diluted EPS | - | -17.57 | -1.04 | -0.62 | -0.56 | -0.43 |
| R&D Expense | 14.59M | 25.84M | 28.16M | 22.49M | 22.50M | 17.45M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 71.53M | 202.47M | 134.05M | 94.20M | 58.90M | 55.26M |
| Total Equity | -39.86M | -61.05M | 186.23M | 123.72M | 84.40M | 49.04M | 41.01M |
| Cash & Equivalents | - | 62.68M | 188.50M | 117.47M | 75.18M | 37.65M | 35.09M |
| Total Liabilities | - | 4.29M | 16.25M | 10.33M | 9.80M | 9.86M | 14.26M |
| Current Liabilities | - | 4.12M | 15.74M | 8.80M | 8.77M | 8.73M | 11.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.52M | -47.18M | -72.34M | -41.81M | -38.77M | -27.95M |
| Investing Cash Flow | -1.57M | -2.71M | -585.00K | -804.00K | -383.00K | -1.19M |
| Financing Cash Flow | 60.94M | 176.77M | 7.00K | 174.00K | 1.02M | 27.50M |
| Capital Expenditure | -1.57M | -2.71M | -585.00K | -804.00K | -383.00K | -1.19M |
| Free Cash Flow | -23.09M | -49.89M | -72.92M | -42.61M | -39.15M | -29.13M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | -162.2% | -78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| Operating Margin % | -7,990.1% | -4,336.1% | -1,084.2% | -436.1% | -335.3% | -273.4% |
| Net Margin % | -7,968.4% | -4,335.0% | -1,073.7% | -401.0% | -315.9% | -262.3% |
| ROE % | 38.4% | -34.8% | -59.1% | -52.4% | -83.0% | -86.8% |
| ROCE % | -34.8% | -34.7% | -59.0% | -56.3% | -86.2% | -85.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.14% | 4.67M | $3.67M |
| 2 | Vanguard Capital Management LLC | 3.71% | 3.38M | $2.65M |
| 3 | Geode Capital Management, LLC | 2.15% | 1.96M | $1.54M |
| 4 | Fosun International Ltd | 1.91% | 1.74M | $1.37M |
| 5 | Catalio Capital Management, LP | 1.45% | 1.32M | $1.04M |
| 6 | State Street Corporation | 1.12% | 1.02M | $798.02K |
| 7 | Renaissance Technologies, LLC | 1.04% | 945.84K | $742.20K |
| 8 | Alphabet Inc. | 0.99% | 898.72K | $705.23K |
| 9 | Northern Trust Corporation | 0.70% | 633.05K | $496.76K |
| 10 | Vanguard Fiduciary Trust Co | 0.62% | 567.11K | $445.01K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HYPR
FDA clears software for a portable brain scanner, adding clearer images and 3D views - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQSUNlZnkwQmFxOGtBai1QejZMVUJmVE5pTm4ydXczMWNlYllSZjQ2dW1jMHk0R2Y0a1c2aGUyRTlSWjEzMjRBN3FmRm5OZVB3VFN5QlJ2eUgxbnV2SDlsUDdLeHY0aTI2NDRLdXhrUjlVSjN2ZHpWMm5NdTVPV21UZy1CVlRWOVdSSnZrSn…
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPSzJ5YzY5bGhEMkhzSXo4QWhQTGJfa0NtVmVnNzdIZkduaEVmaHdQX3VYTzhpQWR6X0d1dERkUkhnUGczaTcycWlqa2dHbzhLY1g3OHd3eEpvTzk4OWtzYTYtT3lJQVAyZm9YdGx3ZUtPVnU3Y3FpeTA2Um5mZXlENlZ6c3dFaXpWQWtNSX…
Hyperfine, Inc. (NASDAQ:HYPR) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQSzJVUHpUdVNGVGZ2R3RoVkdNOHlLVVY2RzJEXzM0WVJ4OVo5ZmltOE03alROSXVMamRTTDhsc05vc1hZX3d6N0hHUzBCYUllMVoyQklNOV9FTTJrQjk5eHg3OTZrS2hkS3JkZ3JlWkIzeGZmRU44RWliNmptQzNFTnpRZlJxVmVKV21yQ0…
HYPR - Hyperfine Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFB1bEhCTHR5UUVBbC1LV2xQOTFsSUxNUDNaZHVwaHVPNENaMGtuTm9KNnd0Ml91eS1YZ1pmbHExOWcwaV93LUE?oc=5" target="_blank">HYPR - Hyperfine Inc Stock Price and Quote</a> <font color="#…
$HYPR stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPV1U0NTh4empobVJNM1VnQ0FRZTRCQVNwcGlYaUlWN0hGdVRyUi0tZmtRSm8zanZzenhrRVdCYmtGVlBmbFFXd3NuYUxLVmJPSElnazRxLVVOZzM0ZlV3ZGJGd0xENmZmbnAtdlMycG9jdkFQWEhnajl0UFVtZUxycHpfdTZ3SXk4NV9HYj…
AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE95Z3JXNTNRUV9OZjVGLThrYktRWlNGSjFLb21LQ0N2S0hUODFtX0dLNHdFZENzNkx6SnBUM0J2bV93clRKVUs4QzkyWkpOak1wdU0xM193MXpNdGl3ZUZFTjVVZjE?oc=5" target="_blank">AI Investing Insights - Official…
HYPR — Frequently Asked Questions
What is the current share price of Hyperfine, Inc. (HYPR)?
As of 2026-09-19 21:16 PDT, Hyperfine, Inc. (HYPR) trades at $0.82 on NasdaqGM. Its 52-week range is $0.81 to $2.20.
What is the market capitalisation of HYPR?
Hyperfine, Inc. (HYPR) has a market capitalisation of $74.61M on NasdaqGM.
What is the P/E ratio of HYPR?
HYPR trades at a trailing price-to-earnings (P/E) ratio of -2.22. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.26.
What is the return on equity (ROE) of HYPR?
HYPR has a return on equity (ROE) of -96.97%. Its return on capital employed (ROCE) is -85.19%.
Is HYPR a good stock to buy?
This page provides a data-driven analysis of Hyperfine, Inc. (HYPR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.